ANIX
Anixa Biosciences, Inc.
Biotechnology · Healthcare · United States
3.12
close · 2026-10-30
value
77
cheaper than peers77
quality
57
stronger fundamentals57
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -10.3% | 75 |
| cash flow yield, latest year | -6.6% | 73 |
| earnings yield, latest year | -10.9% | 70 |
| earnings yield, 3 years ago | -14.4% | 69 |
| cash flow yield, 1 year ago | -6.8% | 68 |
| cash flow yield, 2 years ago | -5.7% | 67 |
| earnings yield, 1 year ago | -12.5% | 67 |
| cash flow yield, 3 years ago | -6.0% | 65 |
| price to book | 7.46× | 22 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.4% | 66 |
| operating margin | 0.0% | 50 |
| return on equity | -72.0% | 46 |
3 of 4 measures available
Facts
| market cap | $108M |
| free cash flow | -$3.6M |
| employees | 4 |
| first trade | 1983-10-07 |
| next earnings | 2026-09-09 |
| fundamentals updated | 2026-09-09 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.34 | -0.39 | -0.32 | -0.45 | not reported |
| free cash flow | -$7.2M | -$7.3M | -$6.2M | -$6.5M | not reported |
| net income | -$10.9M | -$12.6M | -$9.8M | -$13.6M | not reported |
| revenue | $0 | $0 | $210,000 | $0 | not reported |
| unusual items | not reported | not reported | not reported | $0 | $6,000 |